{"id":"pd-1-inhibitors","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"3-5","effect":"Immune-related pneumonitis"},{"rate":"2-5","effect":"Immune-related hepatitis"},{"rate":"1-3","effect":"Immune-related colitis"},{"rate":"10-15","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PD-1 (programmed death receptor 1) is an immune checkpoint that normally suppresses T cell activity to prevent autoimmunity. Tumors exploit this mechanism by expressing PD-L1 and PD-L2 ligands, which bind PD-1 and inactivate tumor-infiltrating T cells. PD-1 inhibitors restore anti-tumor immunity by blocking this interaction, enabling cytotoxic T lymphocytes to mount an effective response against malignant cells.","oneSentence":"PD-1 inhibitors block the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:00.178Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (specific indication pending phase 3 results)"}]},"trialDetails":[{"nctId":"NCT07496190","phase":"PHASE2","title":"Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":59},{"nctId":"NCT03620019","phase":"PHASE2","title":"Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-09-10","conditions":"Melanoma Stage Iii, Melanoma Stage Iv, Melanoma","enrollment":25},{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT07495215","phase":"PHASE1, PHASE2","title":"A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection","status":"RECRUITING","sponsor":"Yinghua Xu","startDate":"2025-09-11","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":20},{"nctId":"NCT07466238","phase":"NA","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":"Biliary Tract Cancer (BTC)","enrollment":40},{"nctId":"NCT04615988","phase":"","title":"Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2021-06-09","conditions":"Thyroid, PD-1, Cancer","enrollment":17},{"nctId":"NCT07422363","phase":"PHASE1","title":"Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-28","conditions":"Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma","enrollment":30},{"nctId":"NCT06418724","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2026-07-30","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT02821013","phase":"PHASE3","title":"Duration of Anti-PD-1 Therapy in Metastatic Melanoma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2016-10-31","conditions":"Unresectable/Metastatic Melanoma","enrollment":614},{"nctId":"NCT07457281","phase":"PHASE1","title":"GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2026-04-01","conditions":"Head and Neck Squamous Cell Carcinoma HNSCC","enrollment":9},{"nctId":"NCT07281924","phase":"PHASE1, PHASE2","title":"Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Metastatic Melanoma, Liver Metastases","enrollment":15},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT07470840","phase":"PHASE2","title":"SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2027-02-01","conditions":"Locally Advanced or Metastatic Renal Cell Carcinoma","enrollment":27},{"nctId":"NCT03288545","phase":"PHASE1, PHASE2","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-10-11","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms","enrollment":348},{"nctId":"NCT07489989","phase":"PHASE2","title":"Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-05-15","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)","enrollment":30},{"nctId":"NCT07487519","phase":"PHASE2","title":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-25","conditions":"Breast Cancer (Triple Negative Breast Cancer (TNBC))","enrollment":180},{"nctId":"NCT07485114","phase":"","title":"Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors","status":"RECRUITING","sponsor":"Daniel Keizman","startDate":"2025-12-03","conditions":"Renal Cell Carcinoma (Kidney Cancer), Non Small Cell Lung Cancer, Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT07486492","phase":"EARLY_PHASE1","title":"Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2026-03-31","conditions":"Colorectal Cancer Metastatic, Fecal Microbiota Transplantation","enrollment":10},{"nctId":"NCT07477444","phase":"PHASE1, PHASE2","title":"Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-06-01","conditions":"Gastroesophageal Cancer","enrollment":29},{"nctId":"NCT07277439","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-12-16","conditions":"Gastric Cancer","enrollment":48},{"nctId":"NCT07394387","phase":"PHASE2","title":"Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-01-01","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":39},{"nctId":"NCT04181788","phase":"PHASE1, PHASE2","title":"Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-03-18","conditions":"Advanced Malignancies, Non-small-cell Lung Cancer","enrollment":155},{"nctId":"NCT07479485","phase":"PHASE1, PHASE2","title":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","status":"NOT_YET_RECRUITING","sponsor":"Lepu Biopharma Co., Ltd.","startDate":"2026-04","conditions":"Hepatocellular Carcinoma","enrollment":160},{"nctId":"NCT05941741","phase":"PHASE3","title":"IC Plus Low-dose Radiation Plus Cadonilimab in LANPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-01-10","conditions":"Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy","enrollment":380},{"nctId":"NCT05187182","phase":"PHASE1","title":"CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-06-02","conditions":"Gastric Cancer, Esophageal Cancer, Stomach Cancer","enrollment":42},{"nctId":"NCT04375384","phase":"PHASE2","title":"Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2020-07-01","conditions":"Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma","enrollment":38},{"nctId":"NCT05422794","phase":"PHASE1","title":"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-18","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma","enrollment":57},{"nctId":"NCT02973789","phase":"PHASE3","title":"Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)","status":"COMPLETED","sponsor":"NovoCure GmbH","startDate":"2016-12","conditions":"Nonsmall Cell Lung Cancer, NSCLC","enrollment":291},{"nctId":"NCT07403136","phase":"PHASE2","title":"Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":52},{"nctId":"NCT04943848","phase":"PHASE1","title":"rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2022-01-10","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant","enrollment":36},{"nctId":"NCT07472153","phase":"PHASE2, PHASE3","title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","status":"RECRUITING","sponsor":"N.N. Alexandrov National Cancer Centre","startDate":"2025-07-01","conditions":"Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer","enrollment":120},{"nctId":"NCT07472790","phase":"PHASE1","title":"A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma","status":"NOT_YET_RECRUITING","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","startDate":"2026-03-31","conditions":"High-grade Glioma","enrollment":15},{"nctId":"NCT05364086","phase":"","title":"An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester NCORP Research Base","startDate":"2022-04-26","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":2100},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT07469956","phase":"PHASE2","title":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-31","conditions":"Pancreatic Cancer Resectable","enrollment":30},{"nctId":"NCT07466225","phase":"","title":"HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":150},{"nctId":"NCT07468630","phase":"PHASE2","title":"Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-10","conditions":"Colon Adenocarcinoma","enrollment":106},{"nctId":"NCT07359040","phase":"","title":"Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-07-01","conditions":"Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors","enrollment":80},{"nctId":"NCT05338775","phase":"PHASE1","title":"A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-05-25","conditions":"Relapsed/ Refractory Multiple Myeloma","enrollment":74},{"nctId":"NCT07467590","phase":"PHASE2","title":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-01","conditions":"Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response","enrollment":33},{"nctId":"NCT07466303","phase":"PHASE2","title":"Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-03-25","conditions":"Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer","enrollment":84},{"nctId":"NCT07464366","phase":"PHASE2","title":"The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Ji Dongmei","startDate":"2026-03-15","conditions":"Salivary Gland Carcinomas","enrollment":68},{"nctId":"NCT06775743","phase":"PHASE2","title":"ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-01-15","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer","enrollment":53},{"nctId":"NCT05378334","phase":"NA","title":"Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2022-06-15","conditions":"Non-small Cell Lung Cancer","enrollment":82},{"nctId":"NCT05824481","phase":"PHASE2","title":"Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-08","conditions":"Endometrial Cancer, Endometrial Adenocarcinoma","enrollment":32},{"nctId":"NCT07458529","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Seventh Medical Center of PLA General Hospital","startDate":"2026-02-10","conditions":"Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy","enrollment":50},{"nctId":"NCT05824468","phase":"PHASE2","title":"Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-10","conditions":"Cervical Cancer, Cervical Carcinoma","enrollment":30},{"nctId":"NCT07457099","phase":"","title":"Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2026-04-01","conditions":"Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma","enrollment":85},{"nctId":"NCT06933251","phase":"PHASE2","title":"PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-01-20","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":30},{"nctId":"NCT06488482","phase":"PHASE3","title":"Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2024-12-19","conditions":"High-risk Melanoma","enrollment":1792},{"nctId":"NCT07453342","phase":"","title":"Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-01-01","conditions":"Immune-Related Adverse Events","enrollment":500},{"nctId":"NCT06647680","phase":"PHASE2","title":"Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2025-06-01","conditions":"Rectal Cancer Patients","enrollment":35},{"nctId":"NCT06385262","phase":"PHASE2","title":"TOP 2301: Neoadjuvant Chemo for NSCLC","status":"SUSPENDED","sponsor":"Duke University","startDate":"2025-03-17","conditions":"Non Small Cell Lung Cancer","enrollment":126},{"nctId":"NCT07044336","phase":"PHASE3","title":"Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-01","conditions":"Endometrial Cancer, Malignant Solid Tumour","enrollment":700},{"nctId":"NCT06114940","phase":"PHASE2","title":"Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)","status":"TERMINATED","sponsor":"Jinling Hospital, China","startDate":"2022-12-20","conditions":"Renal Cell Carcinoma (RCC)","enrollment":17},{"nctId":"NCT03705806","phase":"","title":"Palliative Thoracic ImmunoRT","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2018-10-03","conditions":"Lung Cancer, Nonsmall Cell, Lung Cancer","enrollment":12},{"nctId":"NCT07231445","phase":"PHASE1","title":"Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2026-03","conditions":"Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT05467670","phase":"PHASE2","title":"Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexander B Olawaiye, MD","startDate":"2023-03-30","conditions":"Ovarian Cancer","enrollment":16},{"nctId":"NCT07445295","phase":"PHASE3","title":"Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2026-03-31","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":558},{"nctId":"NCT03516279","phase":"PHASE2","title":"Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-06-26","conditions":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease","enrollment":40},{"nctId":"NCT07436390","phase":"NA","title":"IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2024-03-31","conditions":"Metastatic Melanoma, Malignant Melanoma, Skin Cancer","enrollment":132},{"nctId":"NCT06457503","phase":"PHASE4","title":"A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"Coherus Oncology, Inc.","startDate":"2024-11-01","conditions":"Nasopharyngeal Cancer Recurrent","enrollment":100},{"nctId":"NCT07262619","phase":"PHASE1, PHASE2","title":"EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors","status":"RECRUITING","sponsor":"Eikon Therapeutics","startDate":"2026-01-22","conditions":"Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer","enrollment":160},{"nctId":"NCT06773910","phase":"PHASE2","title":"BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2025-03-11","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":250},{"nctId":"NCT07110103","phase":"PHASE2","title":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-31","conditions":"SCLC, SCLC, Extensive Stage","enrollment":20},{"nctId":"NCT04104893","phase":"PHASE2","title":"A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-02-20","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":40},{"nctId":"NCT04093323","phase":"PHASE2","title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-11-13","conditions":"HLA-A2 Positive Cells Present, Refractory Melanoma","enrollment":1},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT05671510","phase":"PHASE3","title":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors","status":"RECRUITING","sponsor":"OncoC4, Inc.","startDate":"2023-06-28","conditions":"Non Small Cell Lung Cancer","enrollment":630},{"nctId":"NCT07428252","phase":"NA","title":"Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-03-01","conditions":"Metastatic Malignant Melanoma","enrollment":150},{"nctId":"NCT03774732","phase":"PHASE3","title":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-01-24","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4","enrollment":327},{"nctId":"NCT06802757","phase":"PHASE2","title":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-05-01","conditions":"Breast Cancer","enrollment":72},{"nctId":"NCT07432568","phase":"PHASE2","title":"A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-09","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":30},{"nctId":"NCT07192926","phase":"","title":"Sarcopenia and CRP-TyG Index (CTI) as Predictors of Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2022-11-15","conditions":"Metastatic Non-small Cell Lung Cancer, Neoplasm","enrollment":131},{"nctId":"NCT07422779","phase":"NA","title":"Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-03-01","conditions":"Metastatic Melanoma, Skin Cancer","enrollment":100},{"nctId":"NCT07419464","phase":"PHASE2","title":"5-Fluorouracil Response and Optimization STudy (The FROST Trial)","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-05-31","conditions":"Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck","enrollment":46},{"nctId":"NCT07419932","phase":"","title":"Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer","status":"RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-12-23","conditions":"Thyroid Cancer, Thyroid Neoplasms","enrollment":120},{"nctId":"NCT07416890","phase":"PHASE2","title":"Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2026-02-10","conditions":"Pirtobrutinib, Sintilimab, Central Nervous System Lymphoma","enrollment":24},{"nctId":"NCT07319195","phase":"EARLY_PHASE1","title":"Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)","status":"NOT_YET_RECRUITING","sponsor":"Jennifer Zhang","startDate":"2026-03","conditions":"Breast Cancer","enrollment":32},{"nctId":"NCT06581406","phase":"PHASE2, PHASE3","title":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-12-17","conditions":"Metastatic Uveal Melanoma","enrollment":280},{"nctId":"NCT07417501","phase":"PHASE2","title":"Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-03-01","conditions":"Solid Tumors","enrollment":60},{"nctId":"NCT03463876","phase":"PHASE2","title":"A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-03-08","conditions":"Hepatocellular Carcinoma","enrollment":190},{"nctId":"NCT07407166","phase":"NA","title":"Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2021-05-01","conditions":"Metastatic Melanoma, Melanoma","enrollment":40},{"nctId":"NCT07381699","phase":"PHASE2","title":"MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-02-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":30},{"nctId":"NCT07410520","phase":"PHASE2","title":"PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-07","conditions":"Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":50},{"nctId":"NCT07408063","phase":"PHASE2","title":"A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-02-02","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT07404332","phase":"PHASE1","title":"5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors","status":"NOT_YET_RECRUITING","sponsor":"Mohammed Milhem","startDate":"2026-02-28","conditions":"Solid Tumor, Locally Advanced Solid Tumor, Metastatic Tumor","enrollment":35},{"nctId":"NCT07401199","phase":"","title":"Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","status":"NOT_YET_RECRUITING","sponsor":"Qun Zhao","startDate":"2026-02-05","conditions":"Gastric Cancer (GC), Locally Advanced Gastric Cancer","enrollment":2000},{"nctId":"NCT06964568","phase":"PHASE3","title":"CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-01","conditions":"Esophageal Carcinoma, Radiotherapy, Immunotherapy","enrollment":452},{"nctId":"NCT07401537","phase":"PHASE2","title":"Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-12-31","conditions":"Triple -Negative Breast Cancer, Breast Cancer","enrollment":416},{"nctId":"NCT07400094","phase":"PHASE2","title":"Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC","status":"NOT_YET_RECRUITING","sponsor":"National Medical Research Radiological Centre of the Ministry of Health of Russia","startDate":"2026-02","conditions":"Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Oral Cavity Neoplasm","enrollment":50},{"nctId":"NCT03851614","phase":"PHASE2","title":"Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-04-08","conditions":"Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma","enrollment":90},{"nctId":"NCT07227636","phase":"PHASE2","title":"A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-11-07","conditions":"Colorectal Cancer, Rectal Cancer","enrollment":284},{"nctId":"NCT07393477","phase":"PHASE2","title":"Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2026-02","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC","enrollment":30},{"nctId":"NCT07394192","phase":"PHASE2","title":"Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-02-01","conditions":"Rectal Cancer, Radiotherapy, PD-1 Inhibitor","enrollment":44},{"nctId":"NCT07392073","phase":"","title":"Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-04","conditions":"Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT05700721","phase":"PHASE2","title":"Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-06-02","conditions":"Brain Metastases","enrollment":120},{"nctId":"NCT05142709","phase":"","title":"Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.","status":"COMPLETED","sponsor":"Fudan University","startDate":"2021-10-31","conditions":"Metastatic Esophageal Squamous Cell Carcinoma","enrollment":1197},{"nctId":"NCT07385989","phase":"PHASE2","title":"Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"WEI XU","startDate":"2026-01-25","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":40},{"nctId":"NCT07385664","phase":"PHASE2","title":"Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2026-01-28","conditions":"Resectable Esophageal Cancer","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2533,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PD-1","immunotherapy gourp","Lenvatinib","anti-PD-1 antibodies","Sintilimab"],"phase":"phase_3","status":"active","brandName":"PD-1 Inhibitors","genericName":"PD-1 Inhibitors","companyName":"Jiangsu Cancer Institute & Hospital","companyId":"jiangsu-cancer-institute-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PD-1 inhibitors block the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer. Used for Advanced or metastatic solid tumors (specific indication pending phase 3 results).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":10,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}